NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis
The subcutaneous formulation of Roche’s blockbuster Ocrevus will cut hospital treatment time for patients.
The subcutaneous formulation of Roche’s blockbuster Ocrevus will cut hospital treatment time for patients.
What's Your Reaction?
